Quest Diagnostics Inc. Receives a Sell from Merrill Lynch

By Ryan Adsit

Merrill Lynch analyst Steven Valiquette reiterated a Sell rating on Quest Diagnostics Inc. (NYSE: DGX) on November 11 and set a price target of $78. The company’s shares closed last Friday at $81.46.

According to, Valiquette is a 4-star analyst with an average return of 7.5% and a 50.0% success rate. Valiquette covers the Services sector, focusing on stocks such as Walgreens Boots Alliance, The Advisory Board, and AmerisourceBergen.

Quest Diagnostics Inc. has an analyst consensus of Hold, with a price target consensus of $84.

The company has a one year high of $86.85 and a one year low of $59.66. Currently, Quest Diagnostics Inc. has an average volume of 1.12M.

Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is neutral on the stock. Most recently, in August 2016, Jenne Britell, a Director at DGX sold 4,000 shares for a total of $339,040.

Quest Diagnostics, Inc. is engaged in providing diagnostic testing, information and services that help patients, physicians and others to make better healthcare decisions. The company operates through two segments: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services segment comprised of two parts develops and delivers diagnostic testing, information and services to patients, physicians, health plans, hospitals, ACOs, IDNs, employers and others. It provides diagnostic information services, which includes clinical testing services such as routine testing, gene-based and esoteric testing, anatomic pathology services, as well as related services and insights. The Diagnostic Solutions includes other businesses such as risk assessment services, clinical trials testing, diagnostic products and healthcare information technology. Quest Diagnostics was founded on December 31, 1996 and is headquartered in Madison, NJ.